SCHEDULE: Cormorant Asset Management Boosts Rapport Therapeutics Stake

Cormorant Asset Management and Bihua Chen report a 6.35% beneficial ownership stake in Rapport Therapeutics, Inc. common stock.

Summary

• Cormorant Asset Management, LP and Bihua Chen collectively hold 3,027,521 shares of Rapport Therapeutics, Inc. common stock.
• This represents 6.35% of the company's outstanding common stock.
• The ownership percentage is calculated based on 47,661,138 shares outstanding as of November 3, 2025, as reported in the Issuer's Form 10-Q.
• Both reporting persons share voting and dispositive power over all 3,027,521 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a significant stake by a specialized healthcare investor like Cormorant Asset Management indicates confidence in Rapport Therapeutics, Inc.'s long-term prospects.

Positives

• A significant institutional investor, Cormorant Asset Management, maintains a substantial stake (6.35%) in Rapport Therapeutics, indicating continued confidence in the company's long-term prospects.
• The investment is stated to be in the ordinary course of business, suggesting a passive, long-term investment strategy rather than an activist one.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Rapport Therapeutics, Inc.'s future performance or strategic direction.

Management Comments

• The reporting persons certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Industry Context

StockSavvy.ai notes that Cormorant Asset Management is a prominent healthcare-focused investment firm. Their continued significant stake in Rapport Therapeutics, a biotechnology company, suggests a positive long-term view on the company's drug development pipeline or market potential within the biopharmaceutical sector. Such an investment by a specialized fund can often be seen as a vote of confidence in the company's scientific platform and management team, potentially attracting further investor interest in the competitive biotech landscape.

Comparison to Industry Standards

• StockSavvy.ai observes that a 6.35% stake by a specialized institutional investor like Cormorant Asset Management is a substantial position, often indicative of a high-conviction investment.
• While direct comparisons to specific projects or results are not provided in this filing, such a significant holding is generally viewed favorably, aligning with the investment strategies of other major biotech-focused funds that take meaningful positions in promising early to mid-stage biopharmaceutical companies.
• For instance, similar stakes are often seen in companies like Moderna (MRNA) or BioNTech (BNTX) during their earlier growth phases, where specialized funds identify disruptive potential.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor's stake may instill confidence and potentially influence market perception, suggesting a positive long-term outlook for the company.

Key Dates

Recommendation

While the significant stake by Cormorant Asset Management is a positive indicator of institutional confidence, this Schedule 13G filing is purely an ownership disclosure and does not provide new operational or financial performance data for Rapport Therapeutics, Inc. A seasoned investor would likely maintain their current position, awaiting further fundamental updates on the company's pipeline, clinical trials, or financial results before making a 'buy' or 'sell' decision. The filing confirms a substantial, but not activist, institutional presence.

Keywords

Rapport Therapeutics, Cormorant Asset Management, Bihua Chen, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Institutional Investor, Biotechnology, Pharmaceuticals